Paid Clinical Trials Georgia
Discover 1,803 paid clinical trials in Georgia. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Lomustine with Temozolomide & RadiationTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Sponsor:
NRG Oncology
Location:
Code:
NCT05095376
Conditions
Glioblastoma
Gliosarcoma
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Lomustine
Magnetic Resonance Imaging
Photon Beam Radiation Therapy
Questionnaire Administration
Temozolomide
Mezigdomide & CarfilzomibA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Sponsor:
Bristol-Myers Squibb
Location:
Code:
NCT05552976
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Mezigdomide
Carfilzomib
Dexamethasone
AMT-162Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
Sponsor:
UniQure Biopharma B.V.
Location:
Code:
NCT06100276
Conditions
Amyotrophic Lateral Sclerosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
AMT-162
AtogepantA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Sponsor:
AbbVie
Location:
Code:
NCT05711394
Conditions
Episodic Migraine
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Atogepant
Placebo-Matching Atogepant
PembrolizumabLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT03486873
Conditions
Solid Tumors
Hematologic Malignancies
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Standard of Care (SOC)
Lenvatinib
Olaparib
MK-4280
RavulizumabStudy of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Sponsor:
Alexion Pharmaceuticals, Inc.
Location:
Code:
NCT06291376
Conditions
Immunoglobulin A Nephropathy
IgAN
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ravulizumab
Placebo
Quemliclustat & ChemotherapyStudy of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor:
Arcus Biosciences, Inc.
Location:
Code:
NCT06608927
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Quemliclustat
Placebo
Nab-paclitaxel
Gemcitabine
Observational StudyA Study in Patients with Mixed Dyslipidemia
Sponsor:
Shanghai Argo Biopharmaceutical Co., Ltd.
Location:
Code:
NCT06497127
Conditions
Mixed Dyslipidemia
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BW-00112
CrizanlizumabA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT06439082
Conditions
Sickle Cell Disease
Eligibility Criteria
Sex: All
Age: 12 - 70+
Healthy Volunteers: Not accepted
Interventions
Crizanlizumab
Placebo
PDA TreatmentPREEMIE: Study for Treatment of PDA in Premature Infants
Sponsor:
Merit Medical Systems, Inc.
Location:
Code:
NCT06587282
Conditions
Patent Ductus Arteriosus (PDA)
Eligibility Criteria
Sex: All
Age: 5+
Healthy Volunteers: Not accepted
Interventions
Bloom Micro Occluder System